Distinct different contributions of the alternative and classical complement activation pathway for the innate host response during sepsis.
Complement activation represents a crucial innate defense mechanism to invading microorganisms, but there is an eminent lack of understanding of the separate contribution of the different complement activation pathways to the host response during sepsis. We therefore investigated different innate host immune responses during cecal ligation and puncture (CLP)-induced sepsis in mice lacking either the alternative (fD(-/-)) or classical (C1q(-/-)) complement activation pathway. Both knockout mice strains showed a significantly reduced survival and increased organ dysfunction when compared with control mice. Surprisingly, fD(-/-) mice demonstrated a compensated bacterial clearance capacity as control mice at 6 h post CLP, whereas C1q(-/-) mice were already overwhelmed by bacterial growth at this time point. Interestingly, at 24 h after CLP, fD(-/-) mice failed to clear bacteria in a way comparable to control mice. However, both knockout mice strains showed compromised C3 cleavage during sepsis. Investigating potential causes for this discrepancy, we were able to demonstrate that despite normal bacterial clearance capacity early during the onset of sepsis, fD(-/-) mice displayed increased inflammatory cytokine generation and neutrophil recruitment into lungs and blood when compared with both control- and C1q(-/-) mice, indicating a potential loss of control over these immune responses. Further in vitro experiments revealed a strongly increased Nf-κB activation capacity in isolated neutrophils from fD(-/-) mice, supporting this hypothesis. Our results provide evidence for the new concept that the alternative complement activation pathway exerts a distinctly different contribution to the innate host response during sepsis when compared with the classical pathway.
Department of Anesthesiology and Intensive Care Therapy, Jena University Hospital, Friedrich Schiller University Jena, 07747 Jena, Germany.
Katja
K
Dahlke
Christiane D
CD
Wrann
Oliver
O
Sommerfeld
Maik
M
Sossdorf
Peter
P
Recknagel
Svea
S
Sachse
Sebastian W
SW
Winter
Andreas
A
Klos
Gregory L
GL
Stahl
Yuanyuan Xu
YX
Ma
Ralf A
RA
Claus
Konrad
K
Reinhart
Michael
M
Bauer
Niels C
NC
Riedemann
D000818:Animals; D058491:Bacterial Load / Q000276:immunology; D002432:Cecum; D003167:Complement Activation / Q000235:genetics / Q000276:immunology*; D015922:Complement C1q / Q000172:deficiency / Q000235:genetics; D011416:Complement Factor D / Q000172:deficiency / Q000235:genetics; D003170:Complement Pathway, Alternative / Q000235:genetics / Q000276:immunology*; D003171:Complement Pathway, Classical / Q000235:genetics / Q000276:immunology*; D007113:Immunity, Innate / Q000235:genetics; D007668:Kidney / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D008026:Ligation; D008099:Liver / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D008168:Lung / Q000276:immunology / Q000382:microbiology / Q000503:physiopathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D011677:Punctures; D012772:Shock, Septic / Q000235:genetics / Q000276:immunology* / Q000401:mortality; D016019:Survival Analysis
D015922:Complement C1q; D011416:Complement Factor D
BMC Gastroenterol. 2010 May 05;10:42
20444253
FASEB J. 2004 Feb;18(2):370-2
14688199
FASEB J. 2003 Oct;17(13):1889-91
12897064
J Immunol. 2006 May 15;176(10):6112-20
16670320
J Immunol. 2006 Feb 1;176(3):1769-75
16424207
Int Immunopharmacol. 2002 Oct;2(11):1509-20
12433052
J Immunol. 2006 Sep 15;177(6):4094-102
16951374
Infect Immun. 2005 Dec;73(12):8188-93
16299314
Am J Pathol. 2003 Feb;162(2):449-55
12547703
J Immunol. 2008 Mar 1;180(5):3313-8
18292556
Infect Immun. 2001 Dec;69(12):7304-9
11705901
Mol Immunol. 2007 Sep;44(16):3862-5
17768104
Nat Genet. 1998 May;19(1):56-9
9590289
Nat Med. 2003 May;9(5):517-24
12724763
J Exp Med. 2004 May 17;199(10):1379-90
15148336
Infect Immun. 2004 Sep;72(9):5247-52
15322019
J Clin Invest. 2002 Jul;110(1):101-8
12093893
J Immunol. 2005 Jul 1;175(1):541-6
15972690
J Immunol. 2005 May 15;174(10):6373-80
15879138
Microbes Infect. 2002 Jul;4(8):773-84
12270724
Annu Rev Immunol. 2005;23:821-52
15771587
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16969-74
12477926
J Immunol. 2007 May 1;178(9):5940-8
17442978
Infect Immun. 2004 May;72(5):2899-906
15102802
Immunity. 2003 Aug;19(2):193-202
12932353
Circulation. 2001 Sep 18;104(12):1413-8
11560858
Nat Rev Immunol. 2004 Feb;4(2):133-42
15040586
Cell Immunol. 2007 Feb;245(2):63-9
17507002
J Immunol. 2006 Feb 1;176(3):1305-10
16424154
J Innate Immun. 2010;2(5):439-45
20588003
Nat Med. 1999 Jul;5(7):788-92
10395324
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14577-82
11724962
Mol Immunol. 1996 Feb;33(3):297-309
8649451
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8084-9
16702544
J Immunol. 2002 Oct 15;169(8):4430-6
12370377
Nat Med. 2006 Jun;12(6):682-7
16715088
Am J Pathol. 2000 May;156(5):1549-56
10793066